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Muscarinic Receptor Antagonists, the Overactive Bladder  
and Efficacy against Urinary Urgency
Kylie J. Mansfield
Graduate School of Medicine, University of Wollongong, Northfields Ave, Wollongong, 2522, NSW, Australia.  
email: kylie@uow.edu.au
Abstract: The overactive bladder (OAB) is a debilitating condition in which patients suffer from urinary urgency, frequency and nocturia 
with or without urge urinary incontinence. The mainstay of pharmacotherapy for OAB is muscarinic receptor antagonists, which have 
been shown to be effective treatments for the symptoms of OAB. The mechanism underlying the efficacy of antimuscarinic agents 
against the symptoms of OAB is not completely understood. This review explores the role of bladder mucosal muscarinic receptors in 
the signaling pathways that are activated in response to bladder filling. The cholinergic system is seen to be involved in bladder afferent 
signaling at many levels and as such muscarinic receptor antagonists may affect bladder signaling via numerous pathways including 
release of mediators from the bladder urothelium and activation of suburothelial myofibroblasts and afferent nerves. Therefore the 
mucosal cholinergic system may represent another target for the antimuscarinic agents used to treat OAB.
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The urinary bladder is a largely unappreciated organ. 
In normal adults, the urinary bladder performs the 
vital functions of storing the body’s liquid waste and 
then voiding that waste at a time of our choosing. 
During the storage phase, the bladder accommodates 
approximately 500 mL of urine with the bladder 
wall stretching without any great increase in pres-
sure and without detrusor muscle contractions being 
initiated. At full capacity, the afferent nerves lying 
within the bladder wall signal fullness to the central 
nervous system and at a convenient time voiding is 
initiated. During voiding, the pelvic floor muscles 
relax, and the detrusor muscle contracts until the 
pressure inside the bladder exceeds urethral pres-
sure, at which point voiding occurs. For the major-
ity of individuals, this occurs, about seven or eight 
times each day, without any real thought. However 
for the approximately 17% of men and women over 
the age of 40 years who suffer from an overactive 
bladder (OAB) this normal activity of the bladder 
is disrupted.1,2 Surprisingly, the disruption of blad-
der function associated with OAB is more prevalent 
than other chronic conditions such as heart disease, 
asthma and arthritis.2
Overview of the Overactive Bladder
The overactive bladder (OAB) is a debilitating 
chronic disorder. In 2002, the International Con-
tinence Society defined this condition, in which 
patients typically experience symptoms of urgency 
(a sudden compelling desire to void that cannot be 
deferred), usually with frequency (voiding more 
than eight times in 24 hours) and nocturia (being 
woken at night with the desire to void), with or 
without urge incontinence (the involuntary leakage 
of urine associated with urge).3 OAB is a chronic 
disease with a major negative influence on quality 
of life, especially associated with the limitations it 
places on physical and emotional health, vitality and 
social functioning.4 The symptoms of OAB affect 
all aspects of life including: social (limiting out-
ings due to frequent need to urinate), psychological 
(loss of self esteem associated with incontinence), 
physical (limitations of physical activities due to 
fear of incontinence) and occupational (decreased 
productivity).3 OAB can also be associated with 
economic costs including the personal costs of man-
aging incontinence, the treatment costs  associated 
with managing symptoms and providing care for 
incontinent nursing home residents and costs asso-
ciated with decreased work productivity. In the US, 
the economic costs associated with OAB in the 
year 2000 were estimated to be between $12.02 and 
$17.5 billion.4 This makes the economic impact of 
OAB comparable to the economic impact of influ-
enza, arthritis and osteoarthritis.4
As can be seen from the 2002 definition the cor-
nerstone symptom of OAB is urgency.1,5,6 Urgency is 
usually associated with frequency of urination, noc-
turia and urge urinary incontinence although only 
about one third of patients with OAB will experience 
incontinence.2,7 In incontinent patients, urodynamic 
testing demonstrates detrusor overactivity, where 
urine leakage arises from involuntary detrusor con-
traction.8 The aetiology of these involuntary detrusor 
contractions remains unknown.
There are numerous treatment options available for 
patients with OAB including biofeedback, electrical 
stimulation, bladder training and pharmacotherapy, 
either alone or in combination. However, the primary 
treatment for the OAB is pharmacotherapy with mus-
carinic receptor antagonists.9–11
Bladder Physiology and the Role  
of Muscarinic Receptors
The traditional dogma behind the treatment of OAB 
with muscarinic receptor antagonists was based on 
our understanding of the nerves controlling contrac-
tion of the bladder detrusor muscle. During filling, 
the bladder detrusor muscle is relaxed, expanding at 
low pressure. During voiding the parasympathetic 
nerves release acetylcholine onto muscarinic recep-
tors located on the detrusor muscle, causing it to con-
tract.12 Muscarinic antagonists were thought to inhibit 
the activation of these detrusor muscarinic receptors 
and hence inhibit contraction.
There are five subtypes of muscarinic receptors 
(M1–M5) that have been cloned and  pharmacologically 
characterised.13 Muscarinic receptors are G-protein 
coupled receptors. Muscarinic M1, M3 and M5 recep-
tors are coupled to activation of phospholipase C and 
IP3 production leading to release of calcium from 
intracellular stores.14 In contrast, M2 and M4 receptors 
are coupled to inhibition of adenylyl cyclase lead-
ing to a decrease in cAMP and to inhibition of cal-
cium-activated potassium channels.14 In the urinary 
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 bladder, binding and immunoprecipitation studies15–18 
on human detrusor muscle have demonstrated that 
the majority of muscarinic receptors are M2 recep-
tor (~70%) with small populations of M3 (~20%) and 
M1 (~10%) receptors.
18 Functional studies carried out 
in M3 knockout mice
19 and human detrusor strips20,21 
have demonstrated that the small population of M3 
receptors are primarily responsible detrusor contrac-
tion. Nevertheless, there is some evidence from stud-
ies in M2 knockout mice that the large population of 
M2 receptors have some functional importance.
14,22 
M2 receptors enhance the contraction mediated 
by M3 receptors and inhibit relaxation via a decrease 
in cAMP.23,24
The wall of the bladder also contains a mucosal 
layer. The bladder mucosa is made up of the urothe-
lial cell layer, that lines the lumen of the bladder, 
and the lamina propria containing blood vessels, 
nerves and suburothelial myofibroblasts. The blad-
der urothelium is a folded transitional epithelium 
that expands and unfolds as the bladder volume 
increases. The urothelium is made up of large  surface 
umbrella cells, intermediate cells and basal cells 
attached to the basement membrane.  Historically, 
the urothelial cell layer was considered to be an 
inert layer, simply responsible for containing the 
urine within the bladder lumen. However, recent 
evidence has indicated that the bladder urothelium 
has neuronal and sensor properties25 and plays a 
role in the regulation of the activity of the underly-
ing nerve and muscle and as such is involved in the 
initiation of the micturition reflex.
During bladder filling, stretch of the bladder 
wall triggers the release of mediators (such as ATP) 
from the urothelium that signal bladder fullness 
via the underlying afferent nerves.26 Signals from 
these afferent nerves are processed in the brain and, 
at an appropriate time, efferent parasympathetic 
nerves are activated. The control and integration of 
these afferent and efferent signals has been recently 
reviewed.27
Within the bladder wall, muscarinic receptors have 
not only been identified on the bladder detrusor mus-
cle but have also been localized to the urothelium and 
suburothelial myofibroblasts.18,28–32 Radioligand bind-
ing studies in both pig32 and human bladder18 have 
demonstrated M2 (~70%) and M3 (~30%) muscarinic 
receptors in the bladder mucosa. Mucosal muscarinic 
mRNA for M1, M2, M3 and M5 receptors have also 
been demonstrated using RT-PCR studies.18,29,31
Immunohistochemical studies have localised 
muscarinic receptor immunoreactivity to the bladder 
urothelium.29–31 Studies in the human31 and mouse 
urothelium33 have demonstrated a differential distribu-
tion of muscarinic receptor subtypes within the vari-
ous cell layers of the urothelium (see Fig. 1). While 
M2, M3, M4 and M5 receptors were found in all layers 
of the urothelium, the M2 receptors were concentrated 
in the apical umbrella cell layer and M1 receptors were 
found exclusively in the basal cell layer.31,33
Muscarinic M2 and M3 receptors have also been 
localised to the suburothelial myofibroblasts.28,30 In 
patients with OAB, an increase in both M2 and M3 
immunoreactivity on the suburothelial myofibroblasts 
was observed.30 Interestingly the increased immuno-
reactivity correlated with the patients urgency scores30 
indicating a possible role for the muscarinic recep-
tors located on the suburothelial myofibroblasts in the 
pathophysiology of urgency.
Antimuscarinic Agents show clinical 
Efficacy against the Symptom  
of Urgency
Muscarinic antagonists have been repeatedly shown 
to be effective against the symptoms of OAB (for a 
systematic review see reference34). However, in con-
trast to the conventional belief regarding their mech-
anism of action, recent reports have suggested that 
at therapeutic doses muscarinic antagonists do not 
inhibit detrusor contractility.11,35 Despite this, these 
agents do function to increase bladder capacity and 
decrease urgency during bladder filling.35 During 
filling there is no activity of the efferent parasympa-
thetic nerves,36,37 hence, while muscarinic antagonists 
are effective treatments for OAB their actions can-
not be attributed to inhibition of detrusor muscarinic 
receptors.
Since OAB was redefined in 2002 a number of 
studies have evaluated the effectiveness of anti-
muscarinic agents against the symptoms associated 
with bladder filling, such as micturition frequency 
and urgency. Results from a number of these studies 
are summarised in Table 1. Studies included in this 
table were all 12 week, placebo controlled clini-
cal trials that evaluated the effectiveness of some 
of the newer antimuscarinic agents (fesoterodine, 
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solifenacin,  tolterodine and trospium). The clini-
cal outcomes included were micturition frequency, 
urge urinary incontinence and urgency episodes. 
These were determined from a three day bladder 
diary.
It can be seen from the review by Chapple34 and 
the data summarised in Table 1 that treatment with all 
of the muscarinic antagonists included (fesoterodine, 
solifenacin, tolterodine and trospium) is associated 
with some reduction in micturition frequency with a 
mean reduction in micturition frequency greater than 
14% reported for all of these agents (Table 1). These 
antagonists (fesoterodine, solifenacin, tolterodine and 
trospium) have also been shown to effectively reduce 
urge urinary incontinence (Table 1) with an almost 
50% reduction in the number of urge urinary incon-
tinence episodes at the conclusion of the 12 week 
 clinical trials.
In addition to efficacy against micturition fre-
quency and urge urinary incontinence, these 
antagonists have also been seen to reduce the num-
ber of urgency  episodes per 24 hours (Table 1). 
Fesoterodine, tolterodine and trospium inhibit 
urgency episodes by approximately 17% while 
solifenacin reduces urgency episodes by 59%. The 
reasons underlying the improved efficacy of solif-
enacin against urgency are unknown. While it would 
be tempting to postulate that it may be related to the 
high degree of M3 receptor selectivity associated 
with solifenacin (Table 2), other agents with similar 










Micturition frequency Baseline (Placebo) 12.2 (12.1) 11.3 (11.4) 11.9 (12) 12.8 (12.8)
Mean % change (Placebo) -14.1 (-8.4) -20.4 (-11.1) -17.8 (-8.1) -20.5 (-13.8)
Reported significance ** ** ** ***
Urge urinary incontinence Baseline (Placebo) 3.9 (3.7) 1.9 (2.0) 3.7 (3.7) 4.0 (4.1)
Mean % change (Placebo) -47.4 (-28.8) -84.6 (-45) -49.5 (-30.3) -59.5 (-43.6)
Reported significance ** ** * ***
Urgency episodes Baseline (Placebo) 11.7 (11.4) 5.2 (4.7) 9.2 (11.4) 11.3 (9.6)
Mean % change (Placebo) -17.7 (-8.7) -59.1 (-36.2) -16.4 (-9.6) -20.4 (-9.6)
Reported significance ** *** * ***
References 84–86 39,87–89 85,86,89 41,90–92
notes: Reported significance *P , 0.05, **P , 0.001, ***P , 0.0001.
Definitions: Micturition frequency is defined as the number of times a patient passed urine (including incontinence episodes) in a 24 hour period. Urge 
urinary incontinence (UUI) is defined as the number of times the patient experiences involuntary leakage of urine accompanied by or immediately 
preceded by urgency in a 24 hour period. Urgency episodes are defined as the number of times a patient recorded an urgency episode with or without 
incontinence in a 24 hour period.
M3 selectivity (e.g. darifenacin, Table 2) are not 
associated with similar reductions in urgency epi-
sodes (darifenacin reduces the number of urgency 
episodes by 22%).38
In addition to quantifying an effect on the num-
ber of urgency episodes, some studies have also 
evaluated the efficacy of antimuscarinic agents on 
the  severity of urgency. Urgency severity has been 
evaluated according to PPIUS scale39 in which each 
urgency episode is characterised with a score from 0 
to 4; with 0 indicating no urgency, 1 mild urgency, 
2 moderate urgency, 3 severe urgency and 4 urge 
incontinence.39 Using scales such as this, muscarinic 
antagonists such as solifenacin,39 darifenacin,40 oxy-
butynin40 and trospium41 have been shown to reduce 
the severity of urgency episodes. Therefore, indi-
cating that  muscarinic antagonists not only reduce 
micturition frequency and urge urinary incontinence 
episodes but also the number and severity of urgency 
episodes.
These beneficial effects, on the symptoms of 
urgency, raise questions about how urgency is 
sensed. Urgency (a sudden compelling desire to 
void that cannot be deferred) is a pathological sen-
sation42 that is distinct from the gradual buildup of 
sensation that usually accompanies normal blad-
der filling.6 However, insight into the processes 
underlying urgency can be gained from our under-
standing of the normal bladder sensations during 
filling.
 Antimuscarinics and urinary urgency
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Muscarinic Involvement in Afferent 
processes in the Bladder Mucosa
It is believed that filling sensations from the blad-
der are mediated by afferent nerves located in the 
lamina propria of the mucosa. These afferent nerves 
(Aδ and C fibres) are closely associated with both the 
urothelium and the underlying layer of suburothelial 
myofibroblasts.43,44 These nerve fibres are activated by 
stretch and chemical stimuli45,46 with the myelinated 
Aδ fibres thought to be associated with normal mic-
turition processes while the unmyelinated C fibres are 
thought to be responsible for sensations arising from 
painful stimuli.45–47
During filling, stretch of the bladder wall is 
associated with release of mediators from the 
urothelium.26,48–52 Some of these mediators, such 
as ATP26 are thought to stimulate the underlying 
afferent nerves while others, such as nitric oxide 
(NO)53,54 are thought to be inhibitory.55,56 These 
mediators (ATP, NO) are therefore involved in the 
transduction of stretch of the bladder wall during 
filling, into activation of sensory afferent fibres.55,56 
We have recently reported that the concentration of 
ATP in voided urodynamic fluid correlated signifi-
cantly with voided volume in normal and overac-
tive bladders49 suggesting that stretch of the bladder 
wall during filling leads to an incremental release 
of ATP from the urothelium. ATP can then activate 
the underlying afferent nerves, with increased affer-
ent nerve firing associated with bladder filling.57 
Afferent nerve activation occurs via ligand-gated 
P2X3 receptors.
45,51,58 In knockout mice, loss of P2X3 
receptors leads to decreased voiding frequency and 
increased bladder capacity.58
In addition to activating the afferent nerves, ATP 
released from the urothelium can also activate puri-
nergic receptors located on suburothelial myofi-
broblasts. These purinergic receptors may be either 
ligand-gated P2X receptors59 or G-protein coupled, 
P2Y receptors.60 Suburothelial myofibroblasts are 
closely associated with the afferent nerves of the 
lamina propria61,62 and may function to modulate and 
amplify the afferent nerve responses following stretch 
of the bladder wall.43,63
Stretch of the bladder wall has also been 
 associated with release of acetylcholine.37,52,64 Ace-
tylcholine release is not sensitive to the nerve toxin 
tetrodotoxin and is dependent on the presence of 
the urothelium, suggesting that the urothelium is a 
source of non- neuronal acetylcholine.37 The urothe-
lium has been shown to contain the cellular machin-
ery required for the synthesis of acetylcholine, 
including choline acetyltransferase52 and carnitine 
acetyltransferase.56,57,65,66 Acetylcholine is therefore 
another stimulatory agent released from the bladder 
urothelium.
Recent studies have demonstrated that antimus-
carinic agents such as oxybutynin have an inhibi-
tory effect on afferent nerve firing.56,57,66 Systemic 
administration of oxybutynin and  darifenacin signi-
ficantly decreased the firing rate of both Aδ and C 
fibres during bladder filling.57,66 Similarly, long-term 
administration of oxybutynin led to an increase in 
the micturition interval and increased bladder capac-
ity together with decreased c-Fos expression in the 
spinal cord, which is associated with decreased 
activity of afferent nerves.67 In contrast, intravesi-
cal administration of muscarinic agonists, carbachol 
and oxotremorine, leads to increased excitability of 
bladder afferents, as seen by a decrease in the inter-
 contraction interval.54,68,69 Although, instillation of 
low concentrations of oxotremorine was also asso-
ciated with an inhibitory effect on bladder afferents 
 mediated by NO.54
Stimulation of the bladder mucosa by the muscar-
inic agonist carbachol also leads to the release of an as 
yet unidentified “urothelial derived inhibitory factor” 
(UDIF).32,70,71 Release of UDIF is mediated via activa-
tion of muscarinic M2 receptors.
72 UDIF released fol-
lowing activation of muscarinic receptors functions 
to directly inhibit detrusor muscle contractions. This 
effect can be observed in an organ bath and hence is 
independent of any stimulatory or inhibitory effects of 
muscarinic agonists on bladder afferent nerve fibres.
The mechanism underlying the effect of antimus-
carinic agents on afferent nerve function remains 
Table 2. Reported affinity for antimuscarinic agents 
against human muscarinic receptors expressed in  Chinese 
 Hamster Ovary cells (data summarized from93).
M1 M2 M3 M4 M5
Fesoterodine 15.9 2.5 46.4 10.4 1.5
Darifenacin 65.8 116 3.7 33.1 24.2
Tolterodine 15.9 10.1 5.5 2.7 2.4
Solifenacin 83.9 93.5 19.3 18.5 35.0
Trospium 3.5 1.1 1.2 1.4 6.1
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uncertain, however it is likely to involve mucosal 
muscarinic receptors.18,28–32 A possible mechanism 
is summarised in Figure 1. Acetylcholine released 
from the urothelium in response to stretch52,64 could 
act in an autocrine or paracrine manner to stimulate 
 urothelial muscarinic receptors and trigger the release 
of ATP.50 The ATP released may then facilitate the 
generation of afferent nerve activity either directly, 
via P2X3 receptors, or indirectly via activation of 
purinergic receptors on located the suburothelial 
 myofibroblasts. In addition, acetylcholine could also 
activate the muscarinic receptors located on the subu-
rothelial myofibroblasts.28,30
Mucosal Muscarinic Receptors  
as Therapeutic Targets
Mucosal muscarinic receptors may therefore represent 
another target for antimuscarinic therapy. Following 
oral administration, antimuscarinic agents may gain 
access to mucosal muscarinic receptors via the blood-
stream. In addition, any antimuscarinic agent excreted 
in the urine unchanged, or as an active metabolite, 
may have direct access to urothelial muscarinic recep-
tors.73 In vivo studies in rat bladder have suggested that 
antimuscarinic agents excreted in the urine may have 
therapeutic potential. In order to examine this, human 
volunteers were administered antimuscarinic agents 
Figure 1. Possible mechanism for cholinergic signaling in bladder activity. During filling stretch of the bladder wall induces release of acetylcholine (and 
ATP) from urothelial cells. This acetylcholine may then activate urothelial muscarinic receptors which stimulates further release of ATP. Both acetylcholine 
and ATP may activate the suburothelial myofibroblasts via muscarinic or purinergic receptors which may in turn alter the activity of the associated afferent 
nerves. ATP can also activate afferent nerves directly via P2X3 receptors. This afferent nerve activity can then signal bladder fullness to the central nervous 
system which in turn activates the parasympathetic efferent nerves to release acetylcholine onto muscarinic receptors located on the detrusor smooth 
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(darifenacin, oxybutynin, solifenacin, tolterodine and 
trospium) at the regularly prescribed dose for 5 days. 
Samples of urine from these volunteers was then 
instilled into rat bladders and the effect on carbachol-
induced detrusor overactivity monitored.68,69,74
Intravesical administration of urine from volun-
teers who took trospium prevented the reduction in 
bladder capacity and inter-contraction interval (detru-
sor overactivity) induced by carbachol.68,69 Similarly, 
urine from volunteers who took solifenacin was able 
to prevent carbachol-induced detrusor overactivity.74 
However, urine from volunteers who took oxybu-
tynin,68,69 tolterodine68,69 or darifenacin74 was unable 
to inhibit carbachol-induced detrusor overactivity. In 
all of these studies68,69,74 the urine was only instilled 
into the bladder for a short period of time in order 
to minimise any absorption across the mucosal wall 
and hence to remove any direct effects on the detrusor 
muscle itself.
Trospium and solifenacin are unusual in that phar-
macokinetic studies have shown that a relatively high 
percentage of the administered dose is excreted in the 
urine unchanged (Table 3). It can therefore be con-
cluded that the ability of some of the antimuscarinic 
agents to prevent carbachol-induced detrusor overac-
tivity is determined by the actions of the unchanged 
drug and/or active metabolite excreted in urine.73 
Interestingly, in clinical trials these two agents (tros-
pium and solifenacin) have been associated with the 
highest percentage  reduction of the number of urgency 
episodes in a 24 hour period (20.4% and 59.1% 
respectively, see Table 1). However, urinary excre-
tion of parent compound or active metabolite is not 
the only requirement for clinical efficacy. Darifena-
cin also reduces the number of urgency episodes by 
a similar percentage38 although urine from volunteers 
taking darifenacin was unable to prevent carbachol-
induced detrusor overactivity74 and this agent is not 
excreted via the urine (Table 3).
Current use of muscarinic receptor antagonists is 
limited by side effects such as dry mouth and consti-
pation, that are associated with the binding of these 
agents to muscarinic receptors located in the salivary 
glands75 and gastrointestinal tract.76,77 These side 
effects result in many patients discontinuing ther-
apy3 and may in part explain why long term clinical 
improvement is only seen in 35% of patients.78 These 
side effects occur due to a lack of organ selectivity 
of antimuscarinic agents.79 In the future, improve-
ments in the bladder selectivity of muscarinic recep-
tor antagonists may be achieved by developing 
muscarinic receptor antagonists that are targeted to 
the bladder mucosa via excretion in the urine or via 
intravesical administration. Some clinical efficacy 
has previously been obtained from intravesical instil-
lation of oxybutynin in patients with OAB.80–82 In 
rats, intravesical administration of oxybutynin was 
associated with greater bladder selectivity83 and as 
discussed above reduces stretch activated afferent 
nerve firing56,57,66 which may be associated with uri-
nary urgency.
conclusions
Over the last 15 years, antimuscarinic agents have 
been shown to be effective treatments for the 
symptoms of OAB including micturition frequency, 
urge urinary incontinence and urgency episodes. 
Previously this therapy was thought to target the 
 muscarinic receptors located on the detrusor muscle, 
however, recent research indicates that this is not the 
case. The mechanism underlying the clinical effi-
cacy of antimuscarinic agents against the symptoms 
of OAB is not completely understood. This efficacy 
is likely to involve interplay between the muscarinic 
receptors located in the bladder mucosa and media-
tors released from the bladder urothelium, including 
ATP and acetylcholine Figure 1. ATP and acetylcho-
line released from the urothelium may act on the 
Table 3. Urinary excretion of antimuscarinic agents.
Darifenacin Oxybutynin solifenacin Tolterodine Trospium
% excreted in urine 69% 77% 6%
% excreted unchanged 3% ,5% 15% 2.4% 60%
% excreted as an active 
metabolite
14%
References 94 95 96 97 95
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suburothelial myofibroblasts and associated afferent 
nerves to mediate the sensations of bladder filling. 
Thus, the cholinergic system is integral to bladder 
afferent signaling and as such muscarinic receptor 
antagonists may affect bladder signaling via numer-
ous pathways.
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